KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Research & Development: 2009-2024

Historic Research & Development for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $120.9 million.

  • Nektar Therapeutics' Research & Development fell 22.21% to $27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.4 million, marking a year-over-year decrease of 4.70%. This contributed to the annual value of $120.9 million for FY2024, which is 5.91% up from last year.
  • Per Nektar Therapeutics' latest filing, its Research & Development stood at $120.9 million for FY2024, which was up 5.91% from $114.2 million recorded in FY2023.
  • Nektar Therapeutics' 5-year Research & Development high stood at $408.7 million for FY2020, and its period low was $114.2 million during FY2023.
  • In the last 3 years, Nektar Therapeutics' Research & Development had a median value of $120.9 million in 2024 and averaged $151.1 million.
  • Its Research & Development has fluctuated over the past 5 years, first slumped by 47.71% in 2023, then grew by 5.91% in 2024.
  • Nektar Therapeutics' Research & Development (Yearly) stood at $408.7 million in 2020, then decreased by 2.06% to $400.3 million in 2021, then crashed by 45.46% to $218.3 million in 2022, then tumbled by 47.71% to $114.2 million in 2023, then rose by 5.91% to $120.9 million in 2024.